{"id":"cefovecin","rwe":[{"pmid":"41742484","year":"2026","title":"Antimicrobial prescribing in dogs and cats with urinary tract disease in a prospective intervention trial.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"41487482","year":"2025","title":"Genetic connections and antimicrobial resistance in dogs and owners Staphylococcus pseudintermedius isolates.","finding":"","journal":"Frontiers in veterinary science","studyType":"Clinical Study"},{"pmid":"41334627","year":"2025","title":"'Knowledge, attitudes and practices' survey of Austrian veterinarians' antibiotic use in clinical practice.","finding":"","journal":"The Veterinary record","studyType":"Clinical Study"},{"pmid":"41210757","year":"2025","title":"Targeting Ubiquitin-Specific Protease 7 (USP7): A Pharmacophore-Guided Drug Repurposing and Physics-Based Molecular Simulation Study.","finding":"","journal":"ACS omega","studyType":"Clinical Study"},{"pmid":"40929873","year":"2025","title":"Assessment of seasonality in antimicrobial susceptibility testing and resistance of urinary Escherichia coli from dogs and cats in the United States (2019 - 2022).","finding":"","journal":"Preventive veterinary medicine","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Elevated post-study BUN","drugRate":"8.25%","severity":"mild","organSystem":""},{"effect":"Elevated serum gamma glutamyl transferase","drugRate":"","severity":"mild to moderate","organSystem":""},{"effect":"Elevated serum alanine aminotransferase","drugRate":"","severity":"mild to moderate","organSystem":""},{"effect":"Elevated post-study ALT","drugRate":"1.37%","severity":"mild","organSystem":""},{"effect":"Elevated post-study creatinine","drugRate":"2.06%","severity":"mild to moderate","organSystem":""},{"effect":"Diarrhea","drugRate":"0.34%","severity":"mild","organSystem":""}],"seriousAdverseEvents":[{"effect":"Death","drugRate":"","severity":"serious"},{"effect":"Anaphylaxis","drugRate":"","severity":"serious"},{"effect":"Acute pulmonary edema","drugRate":"","severity":"serious"},{"effect":"Seizures","drugRate":"","severity":"serious"},{"effect":"Tremors/ataxia","drugRate":"","severity":"serious"},{"effect":"Hemolytic anemia","drugRate":"","severity":"serious"},{"effect":"Facial edema","drugRate":"","severity":"serious"},{"effect":"Injection site necrosis","drugRate":"","severity":"serious"},{"effect":"Vomiting","drugRate":"","severity":"serious"},{"effect":"Lethargy","drugRate":"","severity":"serious"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CEFOVECIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:56.558130+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:13:02.388521+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOVECIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:13:02.707032+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2104475/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:13:03.416721+00:00"}},"allNames":"convenia","offLabel":[],"synonyms":["cefovecin","convenia","cefovecin sodium"],"timeline":[],"aiSummary":"Convenia (CEFOVECIN) is a veterinary antibiotic originally developed by Pfizer and currently owned by Zoetis. It is a small molecule antibiotic used to treat various bacterial infections in dogs and cats. Convenia is FDA-approved for several indications, including skin infections, urinary tract infections, and respiratory infections. It is a patented product, and its commercial status is not off-patent. Key safety considerations include potential side effects such as vomiting, diarrhea, and skin reactions.","brandName":"Convenia","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Convenia (cefovecin) is a third-generation cephalosporin antibiotic that exerts its antibacterial effects by inhibiting the synthesis of the bacterial cell wall, specifically by binding to penicillin-binding proteins (PBPs) and preventing the cross-linking of peptidoglycan chains."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5662","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CEFOVECIN","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:16:25.939197","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:13:05.090702+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"cefovecin","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"018148","UNII":"0D1OL46ZIE","CHEBI":"CHEBI:31375","INN_ID":"8225","RXNORM":"1591901","UMLSCUI":"C1869686","chemblId":"CHEMBL2104475","ChEMBL_ID":"CHEMBL2110625","KEGG_DRUG":"","DRUGBANK_ID":"DB11505","PUBCHEM_CID":"6336480","SNOMEDCT_US":"439183007","SECONDARY_CAS_RN":"141195-77-9","MESH_SUPPLEMENTAL_RECORD_UI":"C516253"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":103,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Jan 21","pmid":"41742484","title":"Antimicrobial prescribing in dogs and cats with urinary tract disease in a prospective intervention trial.","journal":"Journal of veterinary internal medicine"},{"date":"2025","pmid":"41487482","title":"Genetic connections and antimicrobial resistance in dogs and owners Staphylococcus pseudintermedius isolates.","journal":"Frontiers in veterinary science"},{"date":"2025 Dec 3","pmid":"41334627","title":"'Knowledge, attitudes and practices' survey of Austrian veterinarians' antibiotic use in clinical practice.","journal":"The Veterinary record"},{"date":"2025 Nov 4","pmid":"41210757","title":"Targeting Ubiquitin-Specific Protease 7 (USP7): A Pharmacophore-Guided Drug Repurposing and Physics-Based Molecular Simulation Study.","journal":"ACS omega"},{"date":"2025 Dec","pmid":"40929873","title":"Assessment of seasonality in antimicrobial susceptibility testing and resistance of urinary Escherichia coli from dogs and cats in the United States (2019 - 2022).","journal":"Preventive veterinary medicine"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:13:05.090702+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":false,"score":1}}